Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 360 | 41% |
| 2020 | 8 | 299 | 44% |
| 2021 | 7 | 265 | 48% |
| 2022 | 8 | 351 | 51% |
| 2023 | 8 | 370 | 54% |
| 2024 | 7 | 330 | 57% |
| 2025 from claims | – | 366 296–430 | 59% |
| 2026 forecast | – | 377 295–473 | 60% |
| 2027 forecast | – | 388 287–512 | 61% |
| 2028 forecast | – | 399 282–550 | 62% |
| 2029 forecast | – | 410 279–588 | 62% |
| 2030 forecast | – | 421 276–625 | 63% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Utah; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 67% inpatient hospital, 27% hospital outpatient, 5% surgery center. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 57 | 2,787−2.3%/yr | −2.3%/yr | 0.8 | 2% | 3,030 in 2030+1.4%/yr |
| Arizona | 19 | 661−4.1%/yr | −4.1%/yr | 0.9 | 2% | 740 in 2030+1.8%/yr |
| Washington | 14 | 622−9.6%/yr | −9.6%/yr | 0.8 | 5% | 540 in 2030−2.4%/yr |
| Colorado | 10 | 513−4.9%/yr | −4.9%/yr | 1.0 | 3% | 590 in 2030+2.5%/yr |
| Oregon | 9 | 416−2.9%/yr | −2.9%/yr | 1.0 | 3% | 440 in 2030+0.9%/yr |
| Nevada | 5 | 186−18%/yr | −18%/yr | 0.6 | 0% | 150 in 2030−3.1%/yr |
| Idaho | 4 | 149−11%/yr | −11%/yr | 0.7 | 1% | 200 in 2030+5.3%/yr |
| Wyoming | 2 | 118−11%/yr | −11%/yr | 1.1 | 0% | 110 in 2030−0.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 146 | 24,0660%/yr | 0%/yr | 104.71.1× | 45% | 29,100 in 2030+3.2%/yr |
| Skin substitutes & wound grafts | 18 | 5,940+21%/yr | +21%/yr | 16.21.3× | 77% | 5,190 in 2030−2.2%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Kuros Biosciences leads with 48% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 11 companies reported engagement with Utah’s surgeons worth $60K in consulting, speaking, meals and travel tied to these products, about $8,572 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.